PBH
Prestige Consumer Healthcare In
NYSEUSDEQUITY
Healthcare
DELAYED
Last price
51.31
▲ 0.79 (1.56%)
MARKET · —
Price
Open
50.52
Prev close
50.52
Day high
51.37
Day low
49.91
Volume
265.12K
Market cap
$2.43B
P/E (TTM)
14.37
52W range
42.62 – 71.07
Trailing performance
Returnvs SPY
1W
-0.14%
+1.2%
1M
+4.84%
+1.1%
3M
+6.39%
+3.3%
6M
-26.26%
-37.3%
YTD
-16.83%
-29.1%
1Y
-21.12%
-41.1%
3Y
-16.19%
-90.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$2.43B
Enterprise value$4.41B
Revenue (TTM)$1.10B
Gross profit$605.18M
EBITDA$325.37M
Net income$172.01M
EPS (TTM)$3.57
Free cash flow$147.89M
Total cash$89.13M
Total debt$2.07B
Book value / share$40.46
Shares outstanding47.37M
Float46.70M
Short % of float9.73%
Dividend yield—
Beta (5Y)0.33
Valuation & profitability ratios
Trailing P/E14.37
Forward P/E10.10
PEG ratio1.58
Price / sales—
Price / book1.27
EV / revenue3.99
EV / EBITDA13.55
Gross margin54.77%
Operating margin20.83%
Profit margin15.57%
Return on equity9.12%
Return on assets4.58%
Debt / equity107.86
Current ratio3.23
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Total revenue | $1.09B | $1.14B | $1.13B | $1.13B |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $190.30M | $214.60M | $209.34M | -$82.31M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Net income | $190.30M | $214.60M | $209.34M | -$82.31M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.88 | 0.98 | +12.0% |
| Mar 2026 | 1.39 | 1.23 | -11.5% |
| Dec 2025 | 1.16 | 1.14 | -1.4% |
| Sep 2025 | 0.97 | 0.86 | -11.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 1.07 | 7 | $329.13M | +20.1% |
| Next quarter | 1.24 | 7 | $353.10M | +24.6% |
| Current year | 4.59 | 6 | $1.27B | +17.0% |
| Next year | 5.08 | 8 | $1.35B | +6.1% |
Analyst targets & ownership
Mean target$67.80
High target$75.00
Low target$55.00
Implied upside32.14%
Analyst count5
ConsensusBUY
Strong buy / Buy1 / 4
Hold2
Sell / Strong sell0 / 0
Held by insiders1.41%
Held by institutions116.33%
Institutions holding438
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+103.50K
Net buying
Buy transactions
10
105.71K shares
Sell transactions
4
2.21K shares
Net transactions
+14
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
667.51K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 4, 26 | DARECCA JAMES Director |
STOCK | 2.98K | $0 | Direct |
| Aug 4, 26 | KELLY JOHN F. Director |
STOCK | 2.98K | $0 | Direct |
| Aug 4, 26 | BYOM JOHN E Director |
STOCK | 2.98K | $0 | Direct |
| Aug 4, 26 | CLARK CLESTEEN A Director |
STOCK | 2.98K | $0 | Direct |
| Aug 4, 26 | ZIER DAWN M Director |
STOCK | 2.98K | $0 | Direct |
| May 11, 26 | ZERILLO JEFFREY Officer |
SELL | 351 | $18.35K | Direct |
| May 7, 26 | ZERILLO JEFFREY Officer |
SELL | 305 | $16.58K | Direct |
| May 5, 26 | ZERILLO JEFFREY Officer |
SELL | 346 | $19.14K | Direct |
| May 5, 26 | ZERILLO JEFFREY Officer |
SELL | 1.21K | $66.37K | Direct |
| May 4, 26 | LOMBARDI RONALD M Chief Executive Officer |
STOCK | 51.13K | $0 | Direct |
| May 4, 26 | SACCO CHRISTINE Chief Operating Officer |
STOCK | 18.98K | $0 | Direct |
| May 4, 26 | ZERILLO JEFFREY Officer |
STOCK | 5.31K | $0 | Direct |
| May 4, 26 | MEKHAIL ADEL Officer |
STOCK | 7.52K | $0 | Direct |
| May 4, 26 | P POOL WILLIAM General Counsel |
STOCK | 7.86K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BYOM JOHN E |
Director | 54.58K | Stock Award(Grant) |
CLARK CLESTEEN A |
Director | 16.51K | Stock Award(Grant) |
FRITZ MARY BETH |
Officer | 17.37K | Stock Award(Grant) |
HOPKINS SHEILA A |
Director | 30.12K | Stock Award(Grant) |
LOMBARDI RONALD M |
Chief Executive Officer | 378.20K | Stock Award(Grant) |
MEKHAIL ADEL |
Officer | 26.19K | Stock Award(Grant) |
P POOL WILLIAM |
General Counsel | 28.25K | Stock Award(Grant) |
SACCO CHRISTINE |
Chief Operating Officer | 73.89K | Stock Award(Grant) |
ZERILLO JEFFREY |
Officer | 41.81K | Sale |
ZIER DAWN M |
Director | 19.51K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
51.57
-0.50% from price
SMA 20
51.82
-0.98% from price
SMA 50
49.68
+3.27% from price
SMA 100
51.16
+0.29% from price
SMA 200
57.20
-10.30% from price
EMA 12
51.42
-0.21% from price
EMA 26
51.10
+0.42% from price
EMA 50
50.83
+0.94% from price
RSI (14)
51.0
Neutral
MACD (12,26,9)
0.32
Hist -0.30
ATR (14)
1.90
3.70% of price
Realised vol 30D
34.9%
Annualised
Bollinger upper
54.56
20, 2σ
Bollinger lower
49.08
20, 2σ
50 / 200 cross
Death
49.68 vs 57.20
Trend bias
Below 200
-10.30%
Risk profile
Beta vs SPY
-0.00
Less volatile than market
Correlation to SPY
-0.00
Largely independent
Realised vol 30D
34.9%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-35.3%
Peak to trough
Max drawdown 5Y
-49.0%
Peak to trough
ATR 14
1.90
3.70% of price
Beta (reported)
0.33
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
0.00
Positioning, not flow
Max pain
50.00
-2.6% from spot
ATM implied vol
114.5%
Nearest strike to spot
Skew (10% OTM)
-60.6%
Calls bid over puts
Call volume
0
Contracts, this expiry
Put volume
1
Contracts, this expiry
Heaviest call OI
65.00
15 contracts
Heaviest put OI
50.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Prestige Consumer Healthcare (PBH) Bets Big On M&A, But Can Clear Eyes Recover?
Insider Monkey · 9d ago
Prestige Consumer Healthcare (PBH) Q1 2027 Earnings Call Transcript
Motley Fool · 9d ago
PBH or SYK: Which Is the Better Value Stock Right Now?
Zacks · 10d ago
Prestige Consumer Healthcare Inc. to Participate in Canaccord Genuity Annual Growth Conference
GlobeNewswire · 12d ago
Prestige Consumer Healthcare Q1 Earnings Call Highlights
MarketBeat · 14d ago
Prestige Consumer Healthcare (PBH) Is Up 9.2% After Raising 2027 Outlook On Recent Acquisitions
Simply Wall St. · 14d ago
PBH Stock Up on Q1 Earnings and Revenue Beat, Fiscal '27 View Raised
Zacks · 15d ago
Prestige Consumer Healthcare Inc (PBH) (Q1 2027) Earnings Call Highlights: Record Cash Flow and ...
GuruFocus.com · 16d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.